Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Yicai GlobalBioShanghai Week 2026 Opens -- Joining Forces to Build a Global Biopharmaceutical Innovation EcosystemA news report from Yicai Global: On September 17, the BioShanghai Week 2026 opened at Zhangjiang Science Hall in Shanghai. Themed "AI for Biopharma, Health for All," this year's event brings together innovation resources from around the world to...
- CAPR INVESTOR DEADLINE: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before September 28, 2026 DeadlineInvestors who lost money in CAPR after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.
- MADD Canada Unveils New Prince Edward Island Provincial Memorial Monument Honouring Victims of Alcohol- and Drug-Related CrashesToday, MADD Canada will unveil its new Prince Edward Island (PEI) Provincial Memorial Monument, creating a permanent place to remember victims of alcohol- and drug-related crashes. The monument, engraved with the names of 12 victims, is located at Joseph A. Ghiz Memorial Park.
- Capricor Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Capricor Therapeutics, Inc. - CAPRClaimsFiler, a FREE shareholder information service, reminds investors that they have until September 28, 2026 to file lead plaintiff applications in a securities class action lawsuit against Capricor Therapeutics, Inc. ("Capricor" or the...
- AARD IMPORTANT DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AARDWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with Aardvark’s February 13, 2025 initial public offering (“IPO”); and/or (ii) securities between February 13, 2025 and May 14, 2026, both dates inclusive (the “Class Period”), of the important October 13, 2026 lead plaintiff deadline.
- Citizens Commission on Human Rights International Los AngelesCitizens Commission on Human Rights International Issues Parent Recommendations on Psychiatric Drug and Hospital RisksAs reports grow of psychotropic drug harms and some psychiatric hospital staff being prosecuted for child sexual abuse, parents need facts to protect their children.
- ARS PHARMACEUTICALS DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRYWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026 and June 24, 2026, inclusive (the “Class Period”), of the important October 5, 2026 lead plaintiff deadline.
- Robbins LLPCapricor Therapeutics, Inc. Stockholders with Significant Losses Should Contact Robbins LLP Before the Pending September 28, 2026 Lead Plaintiff DeadlineRobbins LLP informs investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities between December 17, 2025 and July 26,...
- Robbins Geller Rudman & Dowd LLPSEPTEMBER 28, 2026 INVESTOR DEADLINE: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - CAPRRobbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026, both dates inclusive (the "Class Period"), have until Monday, September 28, 2026 to seek appointment as lead plaintiff of the Capicor class action lawsuit. Captioned Nkamga v. Capricor Therapeutics, Inc., No. 26-cv-04385 (S.D. Cal.), the Capricor class action...
- Iovance Biotherapeutics, Inc.Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on September 17, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 179,750 shares of Iovance’s common stock to eighteen new, non-executive employees.
- InMed PharmaceuticalsInMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Shareholders' Equity ComplianceInMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, announces that it has received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company that the shareholders' equity of $1,075,007 as reported in the...
- New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older PatientsTeva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data from a discrete choice experiment highlighting preferred healthcare provider (HCP) treatment attributes when selecting a VMAT2 inhibitor for the treatment of TD in older patients (aged ≥55 years). The new findings were presented at Psych Congress, held September 15 – 19, 2026, in New Orleans, LA.